Navigation Links
NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
Date:9/19/2008

ROCKVILLE, Md., Sept. 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the 2008 UBS Global Life Sciences Conference in New York, NY. The conference is being held September 22-25, 2008 at The Grand Hyatt Hotel. Dr. Singhvi will be presenting Thursday, September 25, 2008 at 10:30 am. Eastern Time. Dr. Singhvi will provide an overview of the company's strategy, research and development progress.

A link to the live presentation can be accessed via the Company website at http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

ABOUT NOVAVAX

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
2. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
3. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
4. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
5. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
8. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
9. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
10. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
11. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Columbia, March 27, 2017  Sophiris Bio Inc. ... "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin ... diseases, today reported fourth quarter and full year ... Key Corporate Highlights: ... Prostate Cancer. During 2016, the Company reported successful ...
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... 2017  iCAD (Nasdaq: ICAD), an industry-leading provider ... therapy for the early identification and treatment of ... Premarket Approval (PMA) from the U.S. Food and ... first-of-its-kind, concurrent-read computer aided detection solution for digital ... available on the PowerLook® Breast Health Solutions platform.  ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... it will co-exhibit with technology partners LG Business Solutions at ATARC Federal ... Center in Washington D.C., will provide education and examination into the mobility tools ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
Breaking Medicine News(10 mins):